>
>
Dyspepsia Drugs Market - Indication (Functional, Organic), Drug Type (Proton Pump Inhibitors, H-2-Receptor Antagonists, Antacids, Antibiotics), Medication (Branded, Generic), Mode (OTC, Prescription), Distribution Channel, Global Forecast (2024-2032)
Download Free PDF

Dyspepsia Drugs Market
Get a free sample of this reportGet a free sample of this report Dyspepsia Drugs Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 10
Tables & Figures: 316
Countries covered: 19
Pages: 180
Download Free PDF
Dyspepsia Drugs Market Size
Dyspepsia Drugs Market size accounted for USD 9.7 billion in 2023 and is set to register 4.5% CAGR between 2024 and 2032. The robust growth of this market is majorly attributed to factors such as increasing prevalence of dyspepsia, growing aging population, and rising preference for over the counter (OTC) drugs/medications.
For instance, according to the Journal of Neurogastroenterology and Motility (JNM), the prevalence of functional dyspepsia is estimated to be around 10-40% in western countries, and about 5-30% in Asia. Thus, as the prevalence of dyspepsia continues to increase, there is a growing pool of individuals seeking dyspepsia drugs for alleviating the symptom associated with it, thereby augmenting the market expansion. Additionally, the increasing use of proton pump inhibitors (PPIs), and growing research & development activities for development of novel product is expected to support the growth.
Dyspepsia drugs encompass a range of medications designed to alleviate symptoms associated with dyspepsia, a condition characterized by discomfort or pain in the upper abdomen often related to digestion. Dyspepsia, also known as indigestion, typically includes symptoms such as bloating, discomfort, and pain in the upper abdomen.
COVID-19 Impact
The pandemic had a negative impact on dyspepsia drugs market. The global supply chains for pharmaceuticals faced disruptions due to lockdowns, restrictions on transportation, and challenges in the production and distribution of drugs. This affected the availability of drugs globally. Also, the focus of healthcare systems shifted towards addressing the immediate challenges posed by the pandemic. Non-urgent medical visits, including those related to dyspepsia were postponed, thereby impacting the overall market growth in 2020. However, adoption towards digital health solutions including telemedicine was noted in later half of 2020, resulting in a modest increase in the growth.
Dyspepsia Drugs Market Trends
Dyspepsia Drugs Market Analysis
Based on indication, the market is segmented into functional dyspepsia and organic dyspepsia. The functional dyspepsia segment accounted for USD 6.9 billion in 2023.
Based on drug type, the dyspepsia drugs market is classified into proton pump inhibitors (PPIs), H-2-receptor antagonists, antacids, antibiotics, prokinetics, and antidepressants. The proton pump inhibitors segment is expected to dominate the market throughout the analysis period.
Based on medication, the dyspepsia drugs market is divided into branded and generic. The branded segment is expected to grow at CAGR of 3.4% between 2024 and 2032.
Based on mode, the dyspepsia drugs market is categorized into over-the-counter and prescription. The over-the-counter segment held majority of business share in 2023 and is expected to reach USD 10.3 billion by 2032.
Based on distribution channel, the dyspepsia drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment contributed to the significant market share and was valued at USD 4.9 billion in 2023.
The North America dyspepsia drugs market is expected to reach USD 6.1 billion by 2032 with CAGR of 4.4%.
Dyspepsia Drugs Market Share
The dyspepsia drugs industry is expected to witness dynamic shifts, driven by innovation, changing consumer preferences, and the pursuit of more effective and patient-friendly treatment options. Established players such as AstraZeneca plc, Takeda Pharmaceutical Company Limited, Pfizer, Inc. are prominent contributors, leveraging their diversified portfolio to address dyspeptic symptoms. These companies also invest in research and development to discover novel compounds and formulations for dyspepsia treatment, aiming for improved efficacy and reduced side effects.
Dyspepsia Drugs Market Companies
Prominent players operating in the dyspepsia drugs industry are as mentioned below:
Dyspepsia Drugs Industry News:
The dyspepsia drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Indication, 2018 – 2032 (USD Million)
By Drug Type, 2018 – 2032 (USD Million)
By Medication, 2018 – 2032 (USD Million)
By Mode, 2018 – 2032 (USD Million)
Dyspepsia Drugs Market, By Distribution Channel, 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries: